Trifluridine/tipiracil outcomes in third- or later lines versus placebo in metastatic gastric cancer treatment: An exploratory subgroup analyses from the TAGS study.

229Background: Metastatic gastroesophageal cancer (GC/GEJC) is an aggressive disease with poor prognosis and a median overall survival (mOS) of around 1 year. While new treatments have emerged, the...